JP4972562B2 - 白人個体群の個体の大多数により認識され得るエプスタイン−バーウイルスのｉ型及びｉｉ型潜伏期抗原のｔｃｄ４＋エピトープ、及びその適用 - Google Patents

白人個体群の個体の大多数により認識され得るエプスタイン−バーウイルスのｉ型及びｉｉ型潜伏期抗原のｔｃｄ４＋エピトープ、及びその適用 Download PDF

Info

Publication number
JP4972562B2
JP4972562B2 JP2007553650A JP2007553650A JP4972562B2 JP 4972562 B2 JP4972562 B2 JP 4972562B2 JP 2007553650 A JP2007553650 A JP 2007553650A JP 2007553650 A JP2007553650 A JP 2007553650A JP 4972562 B2 JP4972562 B2 JP 4972562B2
Authority
JP
Japan
Prior art keywords
hla
peptide
ebv
molecule
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007553650A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008529486A (ja
JP2008529486A5 (cg-RX-API-DMAC10.html
Inventor
パンクレ，ヴェロニク
オーリアウルト，クラウド
デピル，ステファン
メイラー，ベルナール
モラレス，オリビエ
ムニエ，ガエタン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Université Lille 2 Droit et Santé
Original Assignee
Université Lille 2 Droit et Santé
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Université Lille 2 Droit et Santé filed Critical Université Lille 2 Droit et Santé
Publication of JP2008529486A publication Critical patent/JP2008529486A/ja
Publication of JP2008529486A5 publication Critical patent/JP2008529486A5/ja
Application granted granted Critical
Publication of JP4972562B2 publication Critical patent/JP4972562B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2007553650A 2005-02-07 2006-02-02 白人個体群の個体の大多数により認識され得るエプスタイン−バーウイルスのｉ型及びｉｉ型潜伏期抗原のｔｃｄ４＋エピトープ、及びその適用 Expired - Fee Related JP4972562B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0501198 2005-02-07
FR0501198A FR2881746B1 (fr) 2005-02-07 2005-02-07 Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
PCT/FR2006/000229 WO2006082313A2 (fr) 2005-02-07 2006-02-02 Epitopes t cd4+ des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus db la population caucasienne et leurs applications

Publications (3)

Publication Number Publication Date
JP2008529486A JP2008529486A (ja) 2008-08-07
JP2008529486A5 JP2008529486A5 (cg-RX-API-DMAC10.html) 2009-02-26
JP4972562B2 true JP4972562B2 (ja) 2012-07-11

Family

ID=35116028

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007553650A Expired - Fee Related JP4972562B2 (ja) 2005-02-07 2006-02-02 白人個体群の個体の大多数により認識され得るエプスタイン−バーウイルスのｉ型及びｉｉ型潜伏期抗原のｔｃｄ４＋エピトープ、及びその適用

Country Status (8)

Country Link
US (1) US20090130134A1 (cg-RX-API-DMAC10.html)
EP (1) EP1861418B1 (cg-RX-API-DMAC10.html)
JP (1) JP4972562B2 (cg-RX-API-DMAC10.html)
AT (1) ATE455791T1 (cg-RX-API-DMAC10.html)
CA (1) CA2596929C (cg-RX-API-DMAC10.html)
DE (1) DE602006011859D1 (cg-RX-API-DMAC10.html)
FR (1) FR2881746B1 (cg-RX-API-DMAC10.html)
WO (1) WO2006082313A2 (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011699A1 (en) * 1993-10-29 1995-05-04 The Trustees Of Boston University Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
AU774861B2 (en) * 1998-02-11 2004-07-08 Douglas V Faller Compositions and methods for the treatment of cystic fibrosis
FR2830940B1 (fr) 2001-10-17 2007-06-15 Commissariat Energie Atomique Procede de selection de ligands d'hla-dp4 et ses applications
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
BRPI0815395A2 (pt) 2007-08-15 2015-02-10 Circassia Ltd Composição, vetor, produto, formulação farmacêutica, me´todo in vitro para determinar se as células t reconhecem um polipeptídeo, e, método in vitro para determinar se um indivíduo se encontra ou está em risco de uma condição.
WO2010105112A1 (en) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Detection of short-chain fatty acids in biological samples
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
WO2011072086A1 (en) 2009-12-08 2011-06-16 Hemaquest Pharmaceuticals, Inc. Methods and low dose regimens for treating red blood cell disorders
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
CA3132353A1 (en) 2012-05-08 2013-11-14 The Johns Hopkins University Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer
CN105555756B (zh) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
CA2971677A1 (en) 2014-12-23 2016-06-30 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
EP4650005A3 (en) 2016-07-15 2026-01-28 Viracta Subsidiary, Inc. Histone deacetylase inhibitors for use in immunotherapy
CN110809716B (zh) 2017-02-12 2023-07-07 百欧恩泰美国公司 基于hla的方法和组合物及其用途
KR20200101394A (ko) 2017-12-20 2020-08-27 글락소스미스클라인 바이오로지칼즈 에스.에이. 엡스타인-바 바이러스 항원 구축물
CA3124457A1 (en) * 2018-12-21 2020-06-25 Biontech Us Inc. Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
TWI853940B (zh) 2019-05-31 2024-09-01 美商維拉克塔股份有限公司 以組蛋白去乙醯酶抑制劑治療病毒相關癌症之方法
IL295241B1 (en) * 2020-02-10 2026-06-01 Univ Johns Hopkins Cancer immunotherapy using allogeneic and tumor-specific T-cell and CD4 cell transfusions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040157780A1 (en) * 1993-11-29 2004-08-12 Epimmune Inc. CTL inducing peptides from c-erb2 (HER-2/neu)
WO1996002563A1 (en) * 1994-07-13 1996-02-01 Cornell Research Foundation, Inc. Epstein-barr virus nuclear antigen 1 protein and its expression and recovery
US20020141995A1 (en) * 1997-06-10 2002-10-03 Irvin Charles G. Method for treatment of inflammatory disease
CA2392456A1 (en) * 1999-11-24 2001-05-31 Oklahoma Medical Research Foundation Assays and therapies for latent viral infection
EP1229043A1 (en) * 2001-01-30 2002-08-07 Cyto-Barr B.V. Peptides derived from Epstein Barr virus (EBV) proteins LMP1, LMP2 and BARF1 antibody reagents reactive therewith
GB0214528D0 (en) * 2002-06-24 2002-08-07 Univ Aberdeen Materials and methods for induction of immune tolerance
AU2003246485A1 (en) * 2002-07-16 2004-02-02 Affinium Pharmaceuticals, Inc. Interactions of the epstein-barr virus protein ebna1, and uses thereof
WO2004041849A1 (en) * 2002-11-07 2004-05-21 The Council Of The Queensland Institute Of Medical Research Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
US20040141995A1 (en) * 2002-12-10 2004-07-22 Rongfu Wang MHC class I-restricted and MHC class II-restricted EBNA1 peptides

Also Published As

Publication number Publication date
US20090130134A1 (en) 2009-05-21
FR2881746B1 (fr) 2007-04-13
JP2008529486A (ja) 2008-08-07
DE602006011859D1 (de) 2010-03-11
WO2006082313A2 (fr) 2006-08-10
WO2006082313A3 (fr) 2007-01-11
FR2881746A1 (fr) 2006-08-11
EP1861418A2 (fr) 2007-12-05
ATE455791T1 (de) 2010-02-15
CA2596929A1 (fr) 2006-08-10
EP1861418B1 (fr) 2010-01-20
CA2596929C (fr) 2015-12-29

Similar Documents

Publication Publication Date Title
JP2008529486A (ja) 白人個体群の個体の大多数により認識され得るエプスタイン−バーウイルスのｉ型及びｉｉ型潜伏期抗原のｔｃｄ４＋エピトープ、及びその適用
Diamond et al. Development of a candidate HLA A* 0201 restricted peptide-based vaccine against human cytomegalovirus infection
McMichael et al. HLA B37 determines an influenza A virus nucleoprotein epitope recognized by cytotoxic T lymphocytes.
US7157091B1 (en) MAGE-A1 peptides presented by HLA class II molecules
CA2142007C (en) Immunomodulatory peptides
DK1409527T3 (en) NOVEL cytotoxic T cell epitopes AND polyepitopes human cytomegalovirus (HCMV), compositions comprising them and diagnostic and prophylactic and therapeutic uses thereof
US9687539B2 (en) CD4+ T survivin epitopes and uses thereof
EP1256352A2 (en) Immunomodulatory peptides
RU2761653C2 (ru) Пептиды и способы для лечения диабета
WO1994004171A9 (en) Immunomodulatory peptides
EP1007079A1 (en) Identification of broadly reactive dr restricted epitopes
US20180207261A1 (en) Human herpesvirus immunotherapy
AU2003236922B2 (en) Materials and methods for inductions of immune tolerance
WO1994004557A1 (en) Immunomodulatory peptides
JP2011525108A (ja) ミッドカインタンパク質に由来する抗ガンワクチンとしての免疫原性ペプチド
Brett et al. Human T cell recognition of influenza A nucleoprotein. Specificity and genetic restriction of immunodominant T helper cell epitopes
US7718575B2 (en) Method of selecting HLA-DP4 ligands and the applications thereof
US10550166B2 (en) Immunogenic peptides of the cyclin B1 tumor antigen
EP2042600A1 (en) A public and immunogenic CD4+ T Cell epitope of the hiv tat protein and its applications
AU1906592A (en) Peptides for use in induction of t cell activation against hiv-1
WO2022244891A1 (ja) ＳＡＲＳ－ＣｏＶ－２由来のＴ細胞エピトープペプチド
US20040115622A1 (en) Mixture of peptides originating from a Nef protein and applications thereof
VON BONIN et al. MHC and Antigen Presentation
Gotch HLA B37 DETERMINES AN INFLUENZA A VIRUS NUCLEOPROTEIN EPITOPE RECOGNIZED BY CYTOTOXIC T LYMPHOCYTES BY ANDREW J. McMICHAEL,* FRANCES M. GOTCH,* AND JONATHAN ROTHBARDt

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110719

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111011

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111219

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20120119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120119

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120313

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120409

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150413

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees